NCT00856479

Brief Summary

We are inviting individuals such as yourself, who have diaphyseal fracture (broken bone) with a non union to participate in this research study. A non-union is a lack of bone healing (bone growth where the break in the bone occurred) after 3 months after the operation. The diaphyseal is an area of a specific bone (usually near the middle) where the fracture occurred. The bones we are interested in are the clavicle (collar bone), tibia (lower leg), femur (upper leg), humerus (upper arm) and forearm (lower arm). Treatment goals for these types of fractures are to minimize later surgeries, to assist the healing process, and to decrease the time to healing. The ability of a patient with non-union (lack of bone healing after 3 months post operation) to return to the work force and to normal activities more quickly not only has a good financial impact on society (community), but also improves over-all physical and mental well-being of the patients. "Infuse" is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. "Infuse" may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention. Although the safety and efficacy of Infuse has been demonstrated through numerous pre-clinical studies, further human clinical trial is needed to evaluate the safety and the power to produce effects of this product particularly with respect to non unions of long bones. The purpose of this study is to evaluate the safety and the power to produce effects of Infuse implanted during treatment of long bone non unions to reduce later surgeries required to augment the healing process and to accelerate the time to healing. Given this, the orthopaedic community has planned this study in order to scientifically establish the most effective treatment method to restore function after this type of injury.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2009

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 26, 2009

Completed
3 days until next milestone

Study Start

First participant enrolled

March 1, 2009

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 5, 2009

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2010

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2013

Completed
Last Updated

November 14, 2022

Status Verified

November 1, 2022

Enrollment Period

1 year

First QC Date

February 26, 2009

Last Update Submit

November 8, 2022

Conditions

Keywords

Infusecost analysisNon union diaphyseal fractureThe efficacy of Infuse BMP 2 in Non union diaphyseal fractures. Also the cost analysis with the amount of time spent in hospital post op.

Outcome Measures

Primary Outcomes (1)

  • cost analysis based on length of hospital stay, allograft, blood products and costs associated with complications and/ or re-admission.

    2 years

Secondary Outcomes (1)

  • Secondary efficacy end points will be the radiographic assessment of healing (RUST scale), the clinical assessment of weight-¬bearing status at 6 months post treatment, and the incidence of additional surgical/medical interventions to promote healing.

    2 years

Study Arms (2)

1 Infuse

ACTIVE COMPARATOR

The patient will receive BMP 2 with allograft

Device: Infuse Bone Morphogenic Protein (BMP) 2

2 Iliac crest autograft

ACTIVE COMPARATOR

Autograft from Patients Iliac Crest and allograft

Procedure: iliac crest autograft

Interventions

"Infuse" is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. "Infuse" may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention.

1 Infuse

A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture

2 Iliac crest autograft

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients must meet all of the following criteria to be eligible for entry into the study:
  • a) Patients must require open surgical treatment of non-union of a diaphyseal fracture of the tibia, humerus, femur, radius or ulna sustained secondary to trauma.
  • c) Patients must be candidates for surgical treatment with an intramedullary nail or locked or unlocked plate.
  • d) Patients must have a fracture of the diaphysis as defined for that specific bone.
  • e) Patients must show radiographic evidence of skeletal maturity (closed epiphyseal plates).

You may not qualify if:

  • Patients with any of the following criteria, are not eligible for entry into the study:
  • Patients requiring mechanical fixation other than Intramedullary nailing or plating (i.e. no external fixation)
  • Patients with fractures that fall outside the diaphysis defined for the specific bone in question, i.e. no metaphyseal fractures.
  • Patients with segmental circumferential bone loss \>4cm.
  • Patients whose fractures are the result of a tumour
  • Patients with known metabolic bone disease (other than osteoporosis) which would negatively impact on the bone healing process.
  • Patients with known sensitivity to collagen.
  • Patients who are pregnant or breastfeeding at the time of study enrolment.
  • Patients currently being treated with radiation, chemotherapy, immunosuppression, or steroid therapy.
  • Patients receiving any other investigational drug or treatment.
  • Patients who have other injuries or conditions such as they are unable to communicate or consent
  • m)Patients with known breast or prostate cancer
  • f) Patients must be able and willing to provide informed consent, to complete study assessments, and to be followed for the period of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Halifax Infirmary

Halifax, Nova Scotia, B3h 1V7, Canada

Location

Study Officials

  • Ross K Leighton, MD

    CDHA

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Orthopedic Surgeon

Study Record Dates

First Submitted

February 26, 2009

First Posted

March 5, 2009

Study Start

March 1, 2009

Primary Completion

March 1, 2010

Study Completion

March 1, 2013

Last Updated

November 14, 2022

Record last verified: 2022-11

Locations